drugtargetreview.com5 天
AI designs peptides for ‘undruggable’ diseases
Discover the groundbreaking AI-based platform that designs peptides to target and destroy previously 'undruggable' ...
drugtargetreview.com5 天
Restoring the gut: VE303’s strategy for C. diff relief
Learn about VE303, a potential first-in-class Live Biotherapeutic Product for preventing recurrent Clostridioides difficile ...
drugtargetreview.com1 天
Promising Alzheimer’s drug earns FDA fast-track designation
Johnson & Johnson is advancing Alzheimer’s research through precision medicine, focusing on tau-targeting therapies like ...
drugtargetreview.com5 天
ITM-11 boosts survival in neuroendocrine tumour trial
ITM announces positive Phase 3 results for ITM-11 in neuroendocrine tumours, paving the way for a potential new treatment ...
drugtargetreview.com6 天
Glox Therapeutics secures £500K to develop antibiotics for cystic fibrosis
Glox Therapeutics has received a portion of a £3 million fund to combat antimicrobial resistance in cystic fibrosis patients. The CF AMR Syndicate, which combines expertise from various sectors ...
drugtargetreview.com5 天
Coherus announces positive Phase II results for liver cancer treatment
Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients. Coherus BioSciences announced the final data from ...